Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate

Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0064822. doi: 10.1128/aac.00648-22. Epub 2022 Oct 26.

Abstract

A ceftazidime-avibactam-resistant KPC-producing Pseudomonas aeruginosa strain was isolated in Argentina from a tracheal aspirate. The patient was treated with ceftazidime-avibactam in combination with other agents for 130 days. Whole-genome sequencing of P. aeruginosa identified a D179Y substitution in the Ω loop of KPC-3, corresponding to KPC-31, integrated at the chromosome. The strain belonged to the sequence type 235/O11 (ST235/O11) high-risk clone. Evaluation of carbapenemase detection assays most used by clinical laboratories failed to identify the isolate as a KPC producer.

Keywords: KPC; Pseudomonas aeruginosa; ceftazidime-avibactam resistance; extensively drug-resistant ST235.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds / pharmacology
  • Azabicyclo Compounds / therapeutic use
  • Bacterial Proteins / genetics
  • Ceftazidime / pharmacology
  • Ceftazidime / therapeutic use
  • Drug Combinations
  • Humans
  • Klebsiella pneumoniae* / genetics
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa* / genetics
  • beta-Lactamases / genetics

Substances

  • avibactam, ceftazidime drug combination
  • Anti-Bacterial Agents
  • Ceftazidime
  • Azabicyclo Compounds
  • beta-Lactamases
  • Drug Combinations
  • Bacterial Proteins